New dual-target CAR-T therapy takes on hard-to-treat plasma cell cancers

NCT ID NCT07416682

Recruiting now Disease control Sponsor: Affiliated Hospital to Academy of Military Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main goals are to check safety and find the best dose, with 20 participants enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK PLASMA CELL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell neoplasm refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK PLASMA CELL NEOPLASMS RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS

Contacts and locations

Locations

the Fifth Medical Center of Chinese People's Liberation Army General Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.